AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.